CAVAD.

Methods	Randomised, blinded trial
Participants	Inclusion criteria Age range 40–80 years After newly ischemic stroke from 3 months to 2 years Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC ≥ 4 Moderate or mild cognitive deficits: MMSE 12–26 Vascular or mixed dementia: Hachinski ischaemic score > 4 Moderate or mild disability: mRS ≤ 4, NIHSS < 20 Informed consent Exclusion criteria Definitive diagnosis of dementia prior to the stroke Cerebral haemorrhage in the past Cerebral embolism resulting from cardiogenic embolus Critically ill: mRS > 4, NIHSS ≥ 20 Immobile person with undiagnosed new stroke Severe cardiac, hepatic or nephric complication Dementia not caused by vascular lesions Other diseases disturbing cognitive evaluation Susceptibility to varieties of allergen Contraindication to cilostazol or aspirin Antiplatelet treatment, anticoagulation or fibrinolysis needed for other diseases Rejected from participation by the patient or the family
Interventions	Cilostazol 100 mg twice daily for 12 months Aspirin 100 mg once daily for 12 months
Outcomes	Primary outcomes: changes in cognitive scores (MMSE, Montreal Cognitive Assessment, Clinical Dementia Rating and Blessed‐Roth (time frame 1 year)
Notes	Requested further information but no response from trial team.

CT: computed tomography; MMSE: Mini‐Mental State Examination; MRI: magnetic resonance imaging; mRS: Modified Rankin Score; NIHSS: National Institutes of Health Stroke Scale.